MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. The company is primarily engaged in the development of Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody. MLTX aims to address significant unmet needs in dermatology and rheumatology through its innovative therapeutic approach.
- Sonelokimab (SLK) - Develops a tri-specific IL-17A and IL-17F inhibiting Nanobody for treating inflammatory diseases such as Hidradenitis Suppurativa, Psoriatic Arthritis, and Psoriasis. SLK offers advantages like high affinity, selective binding, and enhanced tissue penetration due to its small size and albumin-binding domain.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Dr. Jorge Santos da Silva Executive | Chief Executive Officer | Professor and Board Advisor at the School of Medicine at Minho University (Portugal). | Co-founder of MoonLake AG; leads MLTX's development of Nanobody® sonelokimab for inflammatory diseases. | View Report → |
Dr. Kristian Reich Executive | Chief Scientific Officer | Guest-Professor at University Medical Center Hamburg-Eppendorf; Medical Advisor at TFS HealthScience; Board Member at Derma2go AG, Dermagnostix GmbH, and ProDerma Foundation. | Co-founder of MoonLake AG; global clinical leader in dermatology and immunology with over 25 years of experience and 300+ peer-reviewed publications. | |
Matthias Bodenstedt Executive | Chief Financial Officer | None | Former McKinsey Partner; oversees MLTX's financial strategy, including maintaining a strong cash position and supporting clinical development programs. | |
Catherine Moukheibir Board | Director | Chair of Audit Committees at Ironwood Pharmaceuticals, Biotalys, Oxford Biomedica, CMR Surgical, Asceneuron, and DNA Script. | Financial expert with extensive board experience in life sciences companies across the U.S. and Europe. | |
Dr. Andrew Phillips Board | Director | CEO and President of Aleksia Therapeutics, Nexo Therapeutics, and Blossom Bioscience; Director at Enliven Therapeutics and multiple private biotechnology companies. | Leader in life sciences-focused investment management and executive roles in biopharmaceutical companies. | |
Dr. Ramnik Xavier Board | Director | Core Institute Member at Broad Institute; Director of Klarman Cell Observatory and Broad's Immunology Program; Co-Director of Broad's Infectious Disease and Microbiome Program; Professor at Harvard Medical School. | Renowned biomedical researcher specializing in genetic variants, computational biology, and immunology; holds multiple leadership roles at prestigious institutions. | |
Simon Sturge Board | Independent Chairperson | Director at Galapagos NV; Director at two private biotechnology companies, a private consulting company, and a private investment company. | Former CEO of Kymab Ltd and COO of Merck Group Germany; extensive experience in biotechnology and pharmaceutical leadership. | |
Spike Loy Board | Director | Managing Director at BVF Partners L.P.; Director at multiple private biopharmaceutical companies. | Experienced in life sciences investment management and biopharmaceutical company leadership. |
Research analysts covering MoonLake Immunotherapeutics.
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MoonLake Immunotherapeutics AG | 2022 | Deal value and structure: Completed on April 5, 2022, under a Business Combination Agreement dated October 4, 2021, with Helix Acquisition Corp. contributing $134,646,009 (including a $15,000,000 loan repayment), converting Series A preferred to common shares and issuing new classes of shares. Strategic rationale and capabilities: The acquisition advanced the development of Sonelokimab, a novel Nanobody® for treating inflammatory diseases, and repositioned the company with a new Nasdaq listing under MLTX. |
Merck Healthcare KGaA (SLK program) | 2021 | Strategic rationale and capabilities: The SLK program, focused on a tri-specific IL-17A/F nanobody that binds human albumin to extend its half-life, is positioned to be best-in-class for IL-17-driven inflammatory diseases, especially in a $44 billion market, with robust Phase II data in psoriasis supporting its development. Notable aspects: Although detailed deal value and structure were not provided, the acquisition strategically expands MoonLake's asset portfolio to target multiple inflammatory indications and compete against drugs like Bimekizumab. |
Recent press releases and 8-K filings for MLTX.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, styled Bridgewood v. MoonLake Immunotherapeutics, et al., following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly regarding its purported advantages over a competitor's product, BIMZELX.
- On September 29, 2025, following the announcement of the trial results, MoonLake's share price cratered $55.75, representing approximately a 90% decrease.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) and certain of its officers by Bronstein, Gewirtz & Grossman, LLC.
- The lawsuit alleges that MoonLake misrepresented the efficacy of its drug candidate, sonelokimab (SLK), by claiming superiority without evidence and omitting material facts about its comparative performance.
- The complaint states that "disastrous" Phase 3 trial results for SLK revealed the drug's shortcomings, causing MoonLake's stock to lose nearly 90% of its value.
- The class period for the lawsuit is between March 10, 2024, and September 29, 2025, inclusive.
- Investors who suffered a loss in MoonLake have until December 15, 2025, to request to be appointed as lead plaintiff.
- A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX), alleging false and misleading statements concerning the company's business, operations, and prospects.
- The lawsuit covers investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025.
- Allegations include misleading statements about the purported superiority of its drug candidate, sonelokimab (SLK), over traditional monoclonal antibodies.
- On September 28, 2025, MoonLake announced Phase 3 VELA program results showing SLK failed to demonstrate competitive efficacy, which led to the stock price declining $55.75 per share, or 89.9%, to close at $6.24 on September 29, 2025.
- The deadline for investors to move the Court to serve as lead plaintiff is December 15, 2025.
- A securities class action has been filed against MoonLake Immunotherapeutics (MLTX) after the company announced disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- On September 29, 2025, MoonLake's share price plummeted by $55.75, or approximately 90%, following the trial results announcement.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, specifically concerning the purported advantages of its Nanobody structure over traditional monoclonal antibodies.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- A securities class action has been filed against MoonLake Immunotherapeutics (MLTX) after the company reported disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK), intended for hidradenitis suppurativa (HS).
- Following the announcement, MoonLake's share price cratered $55.75, or about 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly regarding the purported superior benefits of its Nanobody structure.
- The Class Period for the lawsuit is from March 10, 2024, to September 29, 2025, with the Lead Plaintiff Deadline set for December 15, 2025.
- A securities class action has been filed against MoonLake Immunotherapeutics (MLTX) following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- On September 29, 2025, MoonLake's share price cratered $55.75, or about 90%, after the announcement of the trial results.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, specifically concerning its purported advantages over a competitor's product, BIMZELX.
- The Class Period for the lawsuit is March 10, 2024, to September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) announced disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK), a treatment for hidradenitis suppurativa (HS).
- Following this announcement, MoonLake's share price cratered $55.75, or about 90%, on September 29, 2025.
- A securities class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., has been filed, alleging MoonLake misled investors about SLK’s trial design and efficacy data.
- The lawsuit claims MoonLake made false and misleading statements regarding SLK's purported advantages over a competitor's FDA-approved product, BIMZELX, despite sharing the same molecular targets.
- The class period for the lawsuit is March 10, 2024, through September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., after reporting disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- Following the announcement, MoonLake's share price cratered $55.75, or about 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly its purported advantages over a competitor's product, BIMZELX.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with the lead plaintiff deadline set for December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK), a treatment for hidradenitis suppurativa (HS).
- On September 29, 2025, MoonLake's share price cratered $55.75, or about 90%, after the announcement of the trial results.
- The litigation alleges MoonLake misled investors about SLK's trial design and efficacy data, specifically regarding its purported advantages over a competitor's FDA-approved product, BIMZELX.
- The Class Period for the lawsuit is from March 10, 2024, to September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
- A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) and certain officers for alleged violations of federal securities laws.
- The lawsuit covers the period between March 10, 2024, and September 29, 2025.
- Allegations include misrepresenting the efficacy and superiority of its drug candidate, sonelokimab (SLK), and knowingly omitting material facts, which led to a nearly 90% stock value loss after "disastrous" Phase 3 trial results.
- Investors have until December 15, 2025, to request to be appointed as lead plaintiff.